ibbtec@unican.es

Skip Navigation LinksInglés (Estados Unidos) > About Ibbtec > Team > Members > member detail

Carla Martínez Estévez

  • IBBTEC. c/ Albert Einstein, 22; 39011 Santander (Spain)
  • carla.martinez@unican.es
  • (+34) 942 206 824
  • Transformation and Metastasis
  • Cancer
  • Department of Cell & Molecular Signalling
Carla Martínez Estévez holds Advanced Technician degrees in Clinical and Biomedical Laboratory (2022) and in Pathological Anatomy and Cytodiagnosis (2024), both obtained at CIFP Manuel Antonio in Vigo. During her training, she completed internships at Vithas Lab and at the Cellular Communication in Cancer and Age-Related Diseases group at CINBIO, led by principal investigator María Mayán Santos.

Since 2024, she has been working as a laboratory technician at the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), within the Transformation and Metastasis research group led by Berta Casar Martínez. She joined the group through the CSIC Youth Employment Fellowship, contributing to cutting-edge cancer research.

​​​Transformation and ​Metastasis

​

​

IBBTEC's Transformation and Metastasis group investigates signaling pathways involved in alterations during cancer and metastasis.

The ultimate goal of these studies is to identify modulators that may represent new therapeutic targets to curb metastasis and that can be directly translated into effective prevention or treatment strategies.

The group has a multidisciplinary approach and uses chick and mouse embryo models, organoids and 3D cultures, clinical samples and molecular and cellular biology techniques, patient-derived xenografts, to translate basic research into translational oncology and clinically relevant outcomes.​

Funding

  • Relevancia funcional de PTPk en la rutaRas-ERK: Implicaciones terapeúticas en melanoma. MICIN(CSIC). 01/01/2017- 31/12/2019. SAF 2015-73364-JIN 
  • Repurposing MAPK inhibitors for the treatment of COVID-19. Proyecto Intramural Especial PIE -CSIC ref 202020E113 15/04/2020-31/12/2023 
  • Bases moleculares de resistencia a quimioterapia en neuroblastoma: identificación de nuevos biomarcadores y dianas terapéuticas. PIE-CSIC. 23/01/2020-present MAPK inhibitors for the treatment of COVID-19. Proyecto Gobierno de Cantabria COVID-19 ORDEN UIC/22/2020. 1/11/2020
  • Mecanismos moleculares que determinan la resistencia a quimioterapia en neuroblastoma. Berta Casar. Proyecto Intramural Especial PIE CSIC 201412 5 9. 1/06/2021- 31/05/2022
  • Definir el mecanismo de activacion de CDCP1 para bloquear metastasis de cancer de mama triple negative. Proyectos de I+D+i. Retos de la Sociedad, del Plan Estatal de Investigación y de Innovación 2017-2020. Referencia PID2020-112760rb-i00. 1/09/2021- 31/8/2024
  • Development of a therapeutic response marker for metastatic melanoma 1/12/2021- 30/11/2023 FERO XXI BFERO2103
  • Investigación preclínica de nuevas terapias dirigidas en Linfoma Cutáneo de Células T. PRECLILINF Proyectos de I+D+i. Retos de la Sociedad, del Plan Estatal de Investigación y de Innovación 2024-2027. 




Berta Casar Martínez (IP)

View more

Saire Edith Córdova Hernández

View more

David Gámiz Cruz

View more

Celia Pérez Irizábal

View more

Sara Valero Díaz

View more
IBBTEC

Instituto de Biomedicina y Biotecnología de Cantabria.
PCTCAN - Cl. Albert Einstein, 22
39011 Santander

Sign In